Lydia Clair should not be prescribed solely for its contraceptive properties. If patient compliance is uncertain and contraception is necessary, then a supplementary non-hormonal contraceptive method should be considered.
Lydia Clair is supplied in blister pack units consisting of 21 tablets. Each tablet contains Cyproterone Acetate 2mg and Ethinyl Estradiol 0.035mg. Each cycle consists of 21 days on medication and a seven days interval without medication (3 weeks on, 1 week off).
First treatment course: The patient is instructed to take 1 tablet daily for 21 consecutive days beginning on day 1 of her menstrual cycle (for the first cycle only the first day of menstrual flow is considered day 1). The tablets are then discontinued for 7 days (one week). Withdrawal bleeding should usually occur during the period that the patient is off the tablets. The first cycle will be somewhat shorter than usual, whereas all following cycles will last 4 weeks.
Subsequent courses: The patient begins her next and all subsequent 21 days course of tablets (following the same 21 days on, 7 days off) on the same day of the week that she began her first course. She begins taking her tablets seven days after discontinuation, regardless of whether or not withdrawal bleeding is still in progress.
Treatment should be continued for several months, since improvement may not be observed with 4 or 5 cycles. It is recommended to continue treatment with Lydia Clair for at least another 3 to 4 cycles after signs have subsided.
Pregnancy should be ruled out before continuing treatment with Lydia Clair in patients who have missed a menstrual period. If pregnancy is suspected, medication should be discontinued.
Special notes on administration: It is recommended that Lydia Clair tablets be taken at the same time each day. Irregular tablet taking, vomiting or intestinal affections with diarrhea, very rare individual metabolic disturbances or prolong simultaneous use of certain medical preparations can affect the contraceptive action (see Precautions and Interactions).
If spotting or breakthrough bleeding occurs during the 3 weeks in which Lydia Clair is being taken, the patient is instructed to continue taking the medication. This type of bleeding usually is transient and without significance. However, if the bleeding is persistent or prolonged, the patient is advised to consult her physician.
In exceptional cases menstruation may fail to occur during the 7 days tablet free interval. The patient is advised not to resume tablet taking and to consult her physician.
Although the occurrence of pregnancy is highly unlikely if the tablets are taken according to directions, possibility of pregnancy should be ruled out before continuing treatment with Lydia Clair in patients who have missed a period of withdrawal bleeding. The patient should consult her physician and in the mean time, a supplementary non-hormonal method of contraception should be employed.
If the patient forgets to take a tablet at the usual time, the tablet may be taken within the next 12 hours. If more than 12 hours have elapsed from the time of usual administration, the patient must discard the missed tablet and continue to take the remaining tablets in the pack at the usual time in order to avoid the premature withdrawal bleeding during this cycle. A supplementary non-hormonal method of contraception must be until the pack is empty to prevent pregnancy, which would necessitate immediate discontinuation of Lydia Clair treatment.
Use of Blister Pack: The patient should be instructed to take the first tablet from the blister pack out of the section marked with the corresponding day of the week, and swallow it whole with some fluid. The patient should be instructed to take the tablet at the same time each day.